Literature DB >> 25082276

MET inhibitors start on road to recovery.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25082276     DOI： 10.1038/nrd4406

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  21 in total

1.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

2.  The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells.

Authors:  Evin İşcan; Aysim Güneş; Peyda Korhan; Yeliz Yılmaz; Esra Erdal; Neşe Atabey
Journal:  J Cell Commun Signal       Date:  2016-12-14       Impact factor: 5.782

3.  Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Authors:  Mansoureh Sameni; Elizabeth A Tovar; Curt J Essenburg; Anita Chalasani; Erik S Linklater; Andrew Borgman; David M Cherba; Arulselvi Anbalagan; Mary E Winn; Carrie R Graveel; Bonnie F Sloane
Journal:  Clin Cancer Res       Date:  2015-10-02       Impact factor: 12.531

Review 4.  Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

Review 5.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

6.  SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.

Authors:  Chang-Yong Yang; Lei Wang; Xing Sun; Mi Tang; Hai-Tian Quan; Lian-Shan Zhang; Li-Guang Lou; Shao-Hua Gou
Journal:  Acta Pharmacol Sin       Date:  2019-01-14       Impact factor: 6.150

7.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Authors:  Robert A Jones; Tyler J Robinson; Jeff C Liu; Mariusz Shrestha; Veronique Voisin; YoungJun Ju; Philip E D Chung; Giovanna Pellecchia; Victoria L Fell; SooIn Bae; Lakshmi Muthuswamy; Alessandro Datti; Sean E Egan; Zhe Jiang; Gustavo Leone; Gary D Bader; Aaron Schimmer; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

Review 8.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

9.  Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

Authors:  Ningfei An; Ying Xiong; Amanda C LaRue; Andrew S Kraft; Bo Cen
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

10.  Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jennifer Weiner; Tony Navas; Yvonne A Evrard; Sonny A Khin; Jiuping Jay Ji; Yiping Zhang; Suzanne Borgel; Thomas D Pfister; Robert J Kinders; Donald P Bottaro; W Marston Linehan; Joseph E Tomaszewski; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2016-03-21       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.